-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPI-2265 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPI-2265 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPI-2265 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Hydroxychloroquine) in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cannabidiol + Hydroxychloroquine) in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Hydroxychloroquine) in Rheumatoid Arthritis Drug Details: IHL-675A, a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BT-8009 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BT-8009 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BT-8009 in Gastric Cancer Drug Details: BT-8009 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – QBS-10072S in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - QBS-10072S in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. QBS-10072S in Metastatic Breast Cancer Drug Details: QBS-10072S is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ruxolitinib Phosphate in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ruxolitinib Phosphate in Oral Cavity (Mouth) Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ruxolitinib Phosphate in Oral Cavity (Mouth) Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Pancreatic Ductal Adenocarcinoma Drug Details: Tislelizumab (Baizean, Tevimbra)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PAC-1 in Neuroendocrine Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PAC-1 in Neuroendocrine Tumors report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PAC-1 in Neuroendocrine Tumors Drug Details: PAC-1 (also known as VO-100)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lu-AG22515 in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lu-AG22515 in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lu-AG22515 in Rheumatoid Arthritis Drug Details: Lu-AG22515 is under development for the...
-
Product Insights
Thymic Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Thymic Carcinoma - Drugs In Development, 2023’, provides an overview of the Thymic Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thymic Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...